Trellis Bioscience discovers and develops novel human antibody therapeutics as treatment for infectious disease and oncology indications. The company leverages its proprietary platform technology, CellSpot™, to find rare human antibodies with superior selectivity, affinity and other characteristics. The company has a pipeline of monoclonal antibodies focused on eliminating difficult infectious diseases; as well as multiple native human antibodies from healthy blood donors against different cancer immune checkpoint targets, a new, and thus far, clinically and commercially successful strategy employed in treating recalcitrant cancers. Trellis also applies CellSpot’s rare antibody capability to identify anti-drug antibodies (ADAs) for pharmaceutical partners. 


Antibodies Targeting LAG-3, TIM-3, KIR Cloned from Healthy Human Donors


Our address as of January 5, 2015:
1505-B O’Brien Drive
Menlo Park, CA  94025